Patents Assigned to KinDex Therapeutics, LLC
  • CIS 3,4-DIHYDROXY-2-(3-METHYLBUTANOYL)-5-(3-METHYLBUTYL)-4-(4-METHYLPENTANOYL)CYCLOPENT-2-EN-1-ONE DERIVATIVES, SUBSTANTIALLY ENANTIOMERICALLY PURE COMPOSITIONS AND METHODS
    Publication number: 20130217781
    Abstract: The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (?)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, activate GPR120, inhibit inflammation, and treat conditions responsive to PPAR? modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes.
    Type: Application
    Filed: March 18, 2013
    Publication date: August 22, 2013
    Applicant: KINDEX THERAPEUTICS, LLC
    Inventor: KINDEX THERAPEUTICS, LLC
  • Cis, 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-derivatives, substantially enantiomerically pure compositions and methods
    Patent number: 8410179
    Abstract: The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (?)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, activate GPR120, inhibit inflammation, and treat conditions responsive to PPAR? modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: April 2, 2013
    Assignee: KinDex Therapeutics, LLC
    Inventors: Brian J. Carroll, Gary Darland, Anuradha Desai, Veera Konda, Clinton J. Dahlberg, Jan Urban
  • CIS 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-derivatives, substantially enantiomerically pure compositions and methods
    Patent number: 8410178
    Abstract: The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (?)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, activate GPR120, inhibit inflammation, and treat conditions responsive to PPAR? modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: April 2, 2013
    Assignee: KinDex Therapeutics, LLC
    Inventors: Brian J. Carroll, Gary Darland, Anuradha Desai, Veera Konda, Clinton J. Dahlberg, Jan Urban